CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings
Beginning Balance (in shares) at Sep. 30, 2023		13,950
Beginning balance at Sep. 30, 2023	$ 102,439	$ 14	$ 99,974	$ 2,451
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expense related to director restricted stock units	259		259
Expense related to employee stock-based compensation	1,314		1,314
Exercise of stock options (in shares)		535
Exercise of stock options	261		261
Common stock surrendered for the exercise of stock options (in shares)		(255)
Common stock surrendered for the exercise of stock options	(1,486)		(1,486)
Net income	3,963			3,963
Ending Balance (in shares) at Mar. 31, 2024		14,230
Ending balance at Mar. 31, 2024	106,750	$ 14	100,322	6,414
Beginning Balance (in shares) at Dec. 31, 2023		14,105
Beginning balance at Dec. 31, 2023	104,802	$ 14	100,186	4,602
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expense related to director restricted stock units	180		180
Expense related to employee stock-based compensation	774		774
Exercise of stock options (in shares)		315
Exercise of stock options	0		0
Common stock surrendered for the exercise of stock options (in shares)		(190)
Common stock surrendered for the exercise of stock options	(818)		(818)
Net income	1,812			1,812
Ending Balance (in shares) at Mar. 31, 2024		14,230
Ending balance at Mar. 31, 2024	$ 106,750	$ 14	100,322	6,414
Beginning Balance (in shares) at Sep. 30, 2024	14,386	14,386
Beginning balance at Sep. 30, 2024	$ 110,132	$ 14	100,270	9,848
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expense related to director restricted stock units	309		309
Expense related to employee stock-based compensation	$ 416		416
Exercise of stock options (in shares)	0
Net income	$ 1,992			1,992
Ending Balance (in shares) at Mar. 31, 2025	14,386	14,386
Ending balance at Mar. 31, 2025	$ 112,849	$ 14	100,995	11,840
Beginning Balance (in shares) at Dec. 31, 2024		14,386
Beginning balance at Dec. 31, 2024	111,439	$ 14	100,463	10,962
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expense related to director restricted stock units	130		130
Expense related to employee stock-based compensation	402		402
Net income	$ 878			878
Ending Balance (in shares) at Mar. 31, 2025	14,386	14,386
Ending balance at Mar. 31, 2025	$ 112,849	$ 14	$ 100,995	$ 11,840